2024
From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff J, Nunes J, Costa G, Sofuoglu M, MacLean R, De Aquino J. From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024, 90: 3036-3053. PMID: 38627909, PMCID: PMC11480258, DOI: 10.1111/bcp.16045.Peer-Reviewed Original ResearchOpioid use disorderChronic painLong-term opioid therapyManagement of chronic painPain management alternativeOpioid-induced analgesiaInnovative treatment optionsManagement of painReverse painCentral sensitizationOpioid therapyPain controlTreatment optionsClinical challengeClinical trialsPainPotential therapeutic applicationsPain experiencePotential of psychedelicsNovel therapeuticsHuman evidenceOpioid crisisNeurobiological substratesOpioidExploration of novel therapeuticsAssessing pain in persons with opioid use disorder: Approaches, techniques and special considerations
Nunes J, Costa G, Weleff J, Rogan M, Compton P, De Aquino J. Assessing pain in persons with opioid use disorder: Approaches, techniques and special considerations. British Journal Of Clinical Pharmacology 2024, 90: 2985-3002. PMID: 38556851, DOI: 10.1111/bcp.16055.Peer-Reviewed Original ResearchOpioid use disorderAssess painPain assessmentPain experienceConcomitant chronic painChronic opioid therapyQuantitative sensory testingVisual analogue scalePain assessment methodsPain assessment toolsComplex psychosocial backgroundImprove pain assessmentOpioid therapyOpioid usePain responseChronic painAnalogue scaleTraditional self-report methodsPainRisk factorsUse disorderOpioidNarrative reviewSelf-report methodsMultidisciplinary teamNavigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era
Weleff J, Christian N, Wang J, Singh M, De Aquino J, Saxon A, Vassallo G. Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era. American Journal On Addictions 2024, 34: 85-92. PMID: 39364597, PMCID: PMC11673400, DOI: 10.1111/ajad.13653.Peer-Reviewed Original ResearchSlow-release oral morphineOpioid use disorderBarriers to OUD treatmentAddiction specialistsOpioid use disorder managementUse disorderOUD treatmentThird-line monotherapyFisher's exact testOpioid use disorder treatmentOff-label prescribingOral morphineAgonist opioidsOpioid agonistsOpioid-related overdoseTherapeutic optionsWithdrawal symptomsNovel therapiesExact testOpioidMOUD prescribingSynthetic opioidsClinical practiceClinical approachCompare respondent characteristics
2023
Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, 35: 377-396. PMID: 38299655, PMCID: PMC10835074, DOI: 10.1080/09540261.2023.2229430.Peer-Reviewed Original ResearchOpioid agonist therapyOpioid use disorderNon-opioid analgesicsUse disordersNon-opioid analgesic therapyAlpha-2 adrenergic agonistsMajor public health concernGlial activation inhibitorNon-opioid therapeuticsNovel analgesic strategiesPotential of cannabinoidsPrior opioid exposureOpioid-dependent individualsOpioid-dependent populationsAbuse liability assessmentPublic health concernAnalgesic strategiesAgonist therapyAnalgesic therapyOpioid exposureOUD treatmentPharmacokinetic interactionsGABAergic drugsSignificant morbidityPain types
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply